HBIONasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
HARVARD BIOSCIENCE INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$8.09+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $36.62M
- P/E (TTM)
- –
- Dividend yield
- –
Harvard Bioscience statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Laboratory Analytical Instruments companies for comparison
Valuation
| Measure | Harvard Bioscience | Industry median |
|---|---|---|
| Market Cap | $36.83M | $230.55M |
| Enterprise Value | $67.01M | $202.97M |
| PS Ratio | 0.42 | 3.11 |
| PB Ratio | 4.96 | 3.14 |
| P/OCF Ratio | 56.57 | 22.35 |
Enterprise value
| Measure | Harvard Bioscience | Industry median |
|---|---|---|
| EV / Sales | 0.76 | 2.92 |
Income (trailing twelve months)
| Measure | Harvard Bioscience | Industry median |
|---|---|---|
| Revenue | $87.81M | $102.39M |
| Gross Profit | $51.07M | $60.36M |
| Operating Income | -$245.00K | -$4.31M |
| Pretax Income | -$10.54M | -$2.26M |
| Net Income | -$10.41M | -$6.57M |
| EBITDA | -$245.00K | -$1.98M |
| EPS (Diluted) | -$2.35 | -$0.07 |
Margins
| Measure | Harvard Bioscience | Industry median |
|---|---|---|
| Gross Margin | 58.2% | 55.1% |
| Operating Margin | -0.28% | -6.04% |
| Pretax Margin | -12.0% | -4.11% |
| Profit Margin | -11.9% | -10.5% |
| EBITDA Margin | -0.28% | -2.67% |
| FCF Margin | -1.27% | -0.30% |
Returns
| Measure | Harvard Bioscience | Industry median |
|---|---|---|
| Return on Equity (ROE) | -89.9% | -19.2% |
| Return on Assets (ROA) | -13.3% | -13.3% |
| Return on Invested Capital (ROIC) | -0.84% | -4.11% |
| Return on Capital Employed (ROCE) | -0.48% | -9.07% |
Growth
| Measure | Harvard Bioscience | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -1.06% | 8.85% |
| FCF Growth (YoY) | -123.1% | 10.6% |
| Revenue Growth (3Y CAGR) | -8.60% | 7.08% |
| Revenue Growth (5Y CAGR) | -3.25% | 11.8% |
Balance sheet
| Measure | Harvard Bioscience | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $6.50M | $37.33M |
| Total Debt | $36.68M | $72.66M |
| Net Cash (Debt) | -$30.18M | $3.92M |
| Net Cash Per Share | -$6.63 | $0.28 |
| Equity (Book Value) | $7.42M | $57.36M |
| Book Value Per Share | $1.63 | $2.81 |
| Tangible Book Value | -$8.13M | $10.71M |
| Working Capital | $21.67M | $54.64M |
Financial position
| Measure | Harvard Bioscience | Industry median |
|---|---|---|
| Current Ratio | 1.87 | 2.50 |
| Quick Ratio | 0.85 | 1.54 |
| Debt / Equity | 4.95 | 0.38 |
Cash flow (trailing twelve months)
| Measure | Harvard Bioscience | Industry median |
|---|---|---|
| Operating Cash Flow | $651.00K | -$653.46K |
| Capital Expenditures | -$1.77M | -$3.69M |
| Free Cash Flow | -$1.12M | -$835.02K |
| FCF Per Share | -$0.25 | -$0.02 |
Efficiency
| Measure | Harvard Bioscience | Industry median |
|---|---|---|
| Asset Turnover | 1.12 | 0.59 |
| Inventory Turnover | 1.65 | 2.21 |
| Revenue Per Employee | $259.02K | $322.57K |
| Profits Per Employee | -$30.71K | -$51.88K |
| Employee Count | 339 | 185 |
Dividends and yields
| Measure | Harvard Bioscience | Industry median |
|---|---|---|
| Earnings Yield | -28.3% | -6.91% |
| FCF Yield | -3.04% | -0.56% |
Shares
| Measure | Harvard Bioscience | Industry median |
|---|---|---|
| Shares Outstanding | 4,552,310 | 44,856,700 |
| Shares Change (YoY) | 1.98% | 3.35% |
| Shares Change (QoQ) | 0.93% | 0.27% |
| Shares Held by Institutions | 29.7% | 63.5% |
Taxes
| Measure | Harvard Bioscience | Industry median |
|---|---|---|
| Income Tax | -$129.00K | $1.52M |
Scores
| Measure | Harvard Bioscience | Industry median |
|---|---|---|
| Altman Z-Score | -2.25 | 1.95 |
| Piotroski F-Score | 3 | 5 |
Calculated by StockData from Harvard Bioscience's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.